A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading ...

A former Ipsen executive, Dishant Gupta, was sentenced to two months in prison for insider trading. He illegally profited ...

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10). * Gross total = total number of ...

Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals for BMX-502, a first-in-class bispecific antibody designed to engage and activate mucosal-associated ...

Ipsen (OTCPK:IPSEY) has secured exclusive global rights for the development and commercialization of STRO-003, an antibody-drug conjugate, from Sutro Biopharma (NASDAQ:STRO), completing the final ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed causing ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

In a report released today, Lucy Codrington from Jefferies maintained a Hold rating on Ipsen (0MH6 – Research Report), with a price target of ...

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, ...

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with ...